Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Investegate announcements from F. Hoffmann-La Roche Ltd, US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Related Keywords

Australia ,Japan ,United States ,Canada ,United Kingdom ,Switzerland ,Brazil ,American ,Nathalie Meetz ,Sileia Urech ,Levi Garraway ,Roche Tecentriq ,Bonnie Addario ,Patrick Barth ,Karsten Kleine ,Genentech ,World Health Organization ,Drug Administration ,Head Of Global Product Development ,Foundation For Lung Cancer ,European Medicines Agency ,Roche Group ,Pharmaceuticals Industry ,Roche Group Media Relations ,American Cancer Society ,Chief Medical Officer ,Global Product ,Real Time Oncology Review ,Programmed Death ,World Health Organization Model Lists ,Essential Medicines ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Health Organization ,Lung Cancer ,Cancer Society ,What Is Lung ,Investegate Announcements ,Investegate Company Announcements ,F Hoffmann La Roche Ltd ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,